{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NRAS-mutant+Advanced+Melanoma",
    "query": {
      "condition": "NRAS-mutant Advanced Melanoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:45:42.682Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06346067",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced or Metastatic NRAS-mutant Melanoma"
      ],
      "interventions": [
        {
          "name": "Naporafenib",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 78,
      "start_date": "2024-04-29",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Englewood, Colorado + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06346067"
    },
    {
      "nct_id": "NCT06208124",
      "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor (Phase 1)",
        "Pancreas Adenocarcinoma",
        "Non-small Cell Lung Cancer",
        "Malignant Melanoma (Cutaneous)"
      ],
      "interventions": [
        {
          "name": "IMM-6-415",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immuneering Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-02-27",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06208124"
    },
    {
      "nct_id": "NCT01320085",
      "title": "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAF or NRAS Mutant Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "MEK162",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2011-03-24",
      "completion_date": "2023-02-06",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 10,
      "location_summary": "Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01320085"
    },
    {
      "nct_id": "NCT02974725",
      "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "LXH254",
          "type": "DRUG"
        },
        {
          "name": "LTT462",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-02-24",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 6,
      "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02974725"
    },
    {
      "nct_id": "NCT03580382",
      "title": "Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Trametinib daily Until PD",
          "type": "DRUG"
        },
        {
          "name": "CDX-3379 (ERBB3 antibody)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3,
      "start_date": "2018-07-06",
      "completion_date": "2018-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-05-20",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 2,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580382"
    },
    {
      "nct_id": "NCT03114319",
      "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)",
        "KRAS G12-mutant NSCLC",
        "Esophageal Squamous Cell Cancer (SCC)",
        "Head/Neck SCC",
        "Melanoma",
        "Advanced Gastrointestinal Stromal Tumors (GIST)",
        "Advanced NRAS/BRAFT wt Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "TNO155",
          "type": "DRUG"
        },
        {
          "name": "TNO155 in combination with EGF816 (nazartinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 227,
      "start_date": "2017-05-26",
      "completion_date": "2025-07-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03114319"
    },
    {
      "nct_id": "NCT03415126",
      "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Malignancy",
        "Neoplasia",
        "Neoplasm",
        "Neoplasm Metastasis",
        "Colon Cancer",
        "Colonic Neoplasms",
        "Colon Cancer Liver Metastasis",
        "Metastatic Cancer",
        "Metastatic Melanoma",
        "Metastatic Colon Cancer",
        "Metastatic Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreas Adenocarcinoma",
        "Pancreas Neoplasm",
        "Metastatic Nonsmall Cell Lung Cancer",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ASN007: ascending doses",
          "type": "DRUG"
        },
        {
          "name": "ASN007 RD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Asana BioSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-01-19",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03415126"
    },
    {
      "nct_id": "NCT01781572",
      "title": "A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic NRAS Mutant Melanoma"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "MEK162",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2013-06",
      "completion_date": "2018-02-20",
      "has_results": true,
      "last_update_posted_date": "2020-12-07",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Detroit, Michigan • New York, New York + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781572"
    },
    {
      "nct_id": "NCT04835805",
      "title": "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Belvarafenib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2021-05-13",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04835805"
    },
    {
      "nct_id": "NCT07584226",
      "title": "A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NRAS Mutation",
        "NRAS-mutant Advanced Melanoma",
        "NRAS-mutant Solid Tumors",
        "NRAS Q61R",
        "NRAS Q61K",
        "NRAS Q61L",
        "NRAS Q61H",
        "NRAS G12D",
        "NRAS G13R",
        "NRAS G13D",
        "NRAS G12V"
      ],
      "interventions": [
        {
          "name": "RLY-8161",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2026-03-09",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T09:45:42.682Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Grand Rapids, Michigan • New York, New York + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07584226"
    }
  ]
}